Hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: clinical practice guidelines from the American Society for Transplantation and Cellular Therapy.
The first expert guidelines for transplanting patients with a rare aggressive blood cancer provide clarity where doctors previously had to navigate treatment decisions alone.
The American Society for Transplantation and Cellular Therapy convened a 17-expert panel using GRADE methodology to publish the first society-level HCT guidelines specifically for BPDCN, an aggressive hematologic malignancy requiring complex multi-modal management. Key recommendations include allogeneic HCT consolidation in first CR, myeloablative conditioning with TBI for fit patients, and routine post-HCT intrathecal chemotherapy, providing standardized management guidance where none previously existed.
What the study was
- Study design
- Clinical practice guideline (GRADE methodology, 17-expert panel)
- Population
- Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) eligible for or being considered for hematopoietic cell transplantation
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Transplantation and cellular therapy
Why it surfaced
First ASTCT practice guidelines for HCT in BPDCN, filling a critical evidence gap for a rare aggressive malignancy; structured expert consensus with GRADE methodology directly informs clinical practice. BPDCN unmet need is high despite rare prevalence. Design quality=2 for structured expert guideline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.